keyboard_arrow_up

Daclatasvir, Asunaprevir, and Peginterferon Lambda (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Daclatasvir, Asunaprevir, and Peginterferon Lambda (Hepatitis C Virus) - Forecast and Market Analysis to 2022 is a new market research publication announced by Reportstack. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics.

Daclatasvir is a DAA being developed by BMS for the treatment of HCV infection. The mechanism of action of daclatasvir involves the inhibition the NS5A protein. NS5A is unique to HCV, and the protein is essential for multiple functions in the viral lifecycle, including HCV RNA replication, despite not having any enzymatic activity.

Scope

- Overview of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Daclatasvir, Asunaprevir, and Peginterferon Lambda including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Daclatasvir, Asunaprevir, and Peginterferon Lambda for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis C
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Daclatasvir, Asunaprevir, and Peginterferon Lambda performance
- Obtain sales forecast for Daclatasvir, Asunaprevir, and Peginterferon Lambda from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China).

To view the table of contents and know more details please visit Daclatasvir, Asunaprevir, and Peginterferon Lambda (Hepatitis C Virus) - Forecast and Market Analysis to 2022.